Case Discussion 2: Systemic Therapy for ER+, PR+, HER2- Breast Cancer
March 19th 2021
Breast oncologists review the appropriateness for treating a patient with ER-positive, PR-positive, HER2-negative breast cancer with systemic therapy, with special considerations regarding sequencing therapy if using a CDK4/6 inhibitor as adjuvant therapy.